Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 317.4% in November

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 175,300 shares, an increase of 317.4% from the November 15th total of 42,000 shares. Based on an average trading volume of 246,400 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.9% of the company’s shares are short sold.

Xilio Therapeutics Price Performance

XLO traded down $0.01 during trading on Wednesday, hitting $1.06. 35,180 shares of the stock traded hands, compared to its average volume of 501,355. The business has a 50 day moving average price of $0.98 and a 200 day moving average price of $0.93. The company has a market cap of $46.43 million, a price-to-earnings ratio of -0.62 and a beta of -0.29. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $1.93.

Institutional Trading of Xilio Therapeutics

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in shares of Xilio Therapeutics by 85.0% during the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after purchasing an additional 155,337 shares in the last quarter. Renaissance Technologies LLC grew its position in Xilio Therapeutics by 18.3% during the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after buying an additional 45,554 shares during the period. Finally, XTX Topco Ltd bought a new stake in Xilio Therapeutics in the second quarter worth about $32,000. Institutional investors own 54.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Raymond James lowered their price objective on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.